search
Back to results

Preschool Supplement to Clonidine in ADHD (Kiddie-CAT) (kiddie-CAT)

Primary Purpose

Attention Deficit Hyperactivity Disorder

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
clonidine
methylphenidate
placebo
Sponsored by
University of Cincinnati
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Attention Deficit Hyperactivity Disorder focused on measuring Attention deficit hyperactivity disorder, ADHD, clonidine, methylphenidate, MPH

Eligibility Criteria

4 Years - 6 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Child with ADHD
  • Child ages 4 through 6
  • Child attending a structured preschool or daycare

Exclusion Criteria:

  • Presence of a tic disorder of any kind or a known active heart disease for which it would be unsafe to use the study drugs
  • Presence of pervasive developmental disorder, autism, mental retardation, or serious psychiatric illness
  • Child not attending a structured preschool or daycare

Sites / Locations

  • University of Rochester Medical Center, Department of Neurology, 919 Westfall Road, Building C
  • University of Cincinnati, Department of Psychiatry, 231 Albert Sabin Way, M: 0559
  • Western Psychiatric Institute and Clinic, ADD Program, 3811 Ohara Street

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

1

2

3

4

Arm Description

clonidine

methylphenidate

methylphenidate and clonidine

Outcomes

Primary Outcome Measures

change in score on the Conners Abbreviated Symptom Questionnaire for Teachers (ASQ-T)

Secondary Outcome Measures

the ASQ-Parent (ASQ-P) and Child Global Assessment Scales (C-GAS). Adverse events were monitored using AE logs, the Pittsburgh Side Effects Rating Scale, vital signs and electrocardiograms.

Full Information

First Posted
December 21, 2006
Last Updated
May 20, 2009
Sponsor
University of Cincinnati
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
search

1. Study Identification

Unique Protocol Identification Number
NCT00414921
Brief Title
Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)
Acronym
kiddie-CAT
Official Title
Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)
Study Type
Interventional

2. Study Status

Record Verification Date
December 2007
Overall Recruitment Status
Completed
Study Start Date
September 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
June 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of Cincinnati
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety and efficacy of two medications--clonidine and methylphenidate--alone or in combination to treat attention deficit hyperactivity disorder in children ages 4 through 6.
Detailed Description
Attention deficit hyperactivity disorder (ADHD) is a disease characterized by one or more symptoms of hyperactivity, impulsivity, or inattention that interfere with school, home, work, or social settings. ADHD does not have clear physical signs that can be seen in an x-ray or a lab test. The disorder only can be identified by looking for certain behaviors, which vary from person to person. This trial will compare the benefits and side effects of two medications--clonidine and methylphenidate (MPH)--used alone or in combination to treat ADHD in children. MPH is approved by the Food and Drug Administration (FDA) for the treatment of ADHD symptoms in children, and clonidine is FDA-approved for the treatment of hypertension in adults. Stimulant medications such as MPH are known to safely and effectively treat many ADHD symptoms. Such medicines, however, do not cure the condition or improve all ADHD symptoms, and the long-term effectiveness of these medications is not well-known. In this study, participants will be randomly selected to receive one of four treatments: 1) clonidine; 2) MPH; 3) clonidine and MPH; or 4) a placebo (an inactive substance). Participation in the study is about 16 weeks, and includes a baseline screening and 5 evaluation visits to assess attention, hyperactivity, overall improvement and general functioning, medication side effects, blood pressure, pulse, and weight.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Attention Deficit Hyperactivity Disorder
Keywords
Attention deficit hyperactivity disorder, ADHD, clonidine, methylphenidate, MPH

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
clonidine
Arm Title
2
Arm Type
Active Comparator
Arm Description
methylphenidate
Arm Title
3
Arm Type
Active Comparator
Arm Description
methylphenidate and clonidine
Arm Title
4
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
clonidine
Intervention Description
Clonidine is FDA-approved for the treatment of hypertension in adults
Intervention Type
Drug
Intervention Name(s)
methylphenidate
Other Intervention Name(s)
MPH
Intervention Description
Methylphenidate is known to safely and effectively treat many ADHD symptoms.
Intervention Type
Other
Intervention Name(s)
placebo
Intervention Description
inactive substance
Primary Outcome Measure Information:
Title
change in score on the Conners Abbreviated Symptom Questionnaire for Teachers (ASQ-T)
Time Frame
at 16 weeks
Secondary Outcome Measure Information:
Title
the ASQ-Parent (ASQ-P) and Child Global Assessment Scales (C-GAS). Adverse events were monitored using AE logs, the Pittsburgh Side Effects Rating Scale, vital signs and electrocardiograms.
Time Frame
at 16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
6 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Child with ADHD Child ages 4 through 6 Child attending a structured preschool or daycare Exclusion Criteria: Presence of a tic disorder of any kind or a known active heart disease for which it would be unsafe to use the study drugs Presence of pervasive developmental disorder, autism, mental retardation, or serious psychiatric illness Child not attending a structured preschool or daycare
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Floyd Randy Sallee, MD/PhD
Organizational Affiliation
University of Cincinnati
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Oscar Bukstein, MD
Organizational Affiliation
Western Psychiatric Institute and Clinic
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Donna Palumbo, PhD
Organizational Affiliation
University of Rochester
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
William Pelham, PhD
Organizational Affiliation
SUNY Buffalo
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Rochester Medical Center, Department of Neurology, 919 Westfall Road, Building C
City
Rochester
State/Province
New York
ZIP/Postal Code
14618
Country
United States
Facility Name
University of Cincinnati, Department of Psychiatry, 231 Albert Sabin Way, M: 0559
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45267-0559
Country
United States
Facility Name
Western Psychiatric Institute and Clinic, ADD Program, 3811 Ohara Street
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)

We'll reach out to this number within 24 hrs